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1 | ARGENTINEAN DEMOGRAPHIC
FEATURES
Located in the southernmost region of Latin America,
Argentina is the largest Spanish‐speaking country in the
world with an estimated area of 2,791,810 sq. km of conti-
nental land (plus 969,464 sq. km of islands and Antarctic
land). It is bordered on the west by Chile, on the north by
Bolivia and Paraguay, and on the east by Brazil, Uruguay,
and the Atlantic Ocean. From a historical and geographical
viewpoint, Argentina can be divided into five regions: cen-
tral (the most populous), west (Cuyo), northwest, northeast,
and south (Patagonia) (Figure 1). The continental area is
divided into 23 provinces plus the capital city, Buenos
Aires, harboring an estimated total population of 44 million
people (INDEC, 2010; United Nations Data, 2017), living
91% in urban areas. Around 65% of the population is con-
centrated in the central region provinces, particularly in the
province of Buenos Aires, with 38.95% of the country
population.
Argentina's population was heavily influenced my
numerous migration waves, mostly from Europe, that
admixed with the original Amerindian communities. Sev-
eral studies (Avena et al., 2012; Homburger et al., 2015;
Seldin et al., 2007) concluded that the ethnical composition
of Argentina is mostly composed by European descent
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(52%–78%), followed by Amerindian (19%–31%), African
(2%–9%), and Asiatic (1%). Although the European genetic
imprint is high, it is estimated that most inhabitants do
have some Amerindian admixture. (Avena et al., 2012).
Additionally, in Argentina inhabit, there were several eth-
nic minorities such as German, Arab, Polish, Jewish,
Armenian, Peruvian, Chilean, Uruguayan, Japanese, Chi-
nese, and Korean.
2 | HEALTH CARE IN ARGENTINA
The healthcare system in Argentina is divided into three
settings: public, social security, and private insurance. The
public system is funded through taxes and is available
free of charge to the entire population. It handles approxi-
mately 46% of the population, mainly those of lower
income, who lack other health coverage. The social secu-
rity setting is comprised of labor union‐based coverage,
funded by mandatory contributions from employers and
registered workers, covering about 44% of the population
(workers, employees, and retirees). The private insurance
setting (for‐profit) is funded by specific payments from
the insured and serves 10% of the population, mainly the
higher income fraction. The three systems are indepen-
dently managed with little interaction between them,
which results in overlapping, inefficiency, and high health
expenditure (about 6.61% of the Gross Domestic Product).
(DEIS, 2010).
The National Ministry of Health has a leading role in
public health policy, being responsible for introducing
specific regulations, and running national health programs
(i.e., immunizations, noncommunicable diseases, sexual
and reproductive health and maternal and child health).
Provincial ministries of health are autonomous in terms of
planning and decision‐making on human resources, pur-
chases, infrastructure, and other actions to provide services
to their people. Given its different settings and administra-
tive jurisdictions, the Argentine healthcare system can be
considered a fragmented model (PNUD, 2011).
There are more than 25 thousand different health centers
countrywide. The combined life expectancy at birth is
76.7 years, which is the third greatest in the region
(80.4 years for women and 73.0 for men) (PAHO/WHO,
2017). The natality and adult mortality rate are 17.9 and
7.7 for every 1000 habitants, and the child death rate is 9.7
per 1,000 births (DEIS, 2015b). In 2015, 99.5% of births
occurred in official health centers, highlighting a high
degree of institutionalized deliveries (Langou & Sachetti,
2017). Although the child mortality rate has been going
down steadily in the last decades, mainly due to improve-
ment in prevention and treatment of infectious diseases and
pre‐ and postnatal nutritional factors, the value is still high,
with congenital defects a major cause (ca. 26%) (DEIS,
2015a).
3 | EARLY GENETIC TESTS IN
ARGENTINA: GENETICS APPLIED
TO FORENSIC STUDIES
Between years 1976 and 1983, Argentina went through one
of the cruelest and bloodiest military dictatorships of Latin
America. About 30,000 people were kidnapped, tortured
and killed, and their bodies remain missing. In Argentina
they are called “Desaparecidos” as disappeared or vanished
by the de facto government. (CONADEP, 1984). Argenti-
na's history of genetics is tightly related to forensic devel-
opment and applications that contributed to solve identity
crimes performed in this dark period.
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Many women undergoing pregnancies or kidnapped
along their children were taken to clandestine detention
centers, where they were tortured, gave birth in subhuman
conditions, separated from their offspring, and ultimately
shot or pushed from airplanes to drown in the Río de la
Plata river—what were called “flights of death”. About 500
kidnapped children were never restored to their biological
families. They were abandoned in the streets, taken to fos-
ter homes or given to foster families of militaries (or
friends of them), erasing their identities and depriving them
of their true biological links and history. This repeated
practice evidences that, in Argentina, there was a system-
atic plan of appropriation and stealing of babies by the
Armed Forces (Nosiglia, 1985).
Year 1984 marked an inflection point in the history of
Science and Human Rights, both in Argentina and the
world. Democracy was again restored, and the grandmoth-
ers of missing children—joined in the “Asociación Abuelas
de Plaza de Mayo” (Grandmothers of Plaza de Mayo Asso-
ciation)—were visited by a delegation of the American
Association for the Advancement of Science (AASS) in
order to develop a scientific method that would allow the
identification of the robbed grandchildren, especially in the
absence of both parents due to forced disappearance. The
method was based in the study of the Histocompatibility
Antigens and Blood Groups inheritance pattern and led to
the development of the first statistical value for the “index
of grandpaternity” (Di Lonardo, Darlu, Baur, Orrego, &
King, 1984). In December of 1984, an 8‐year‐old girl
named Paula Eva Logares Grinspon, previously kidnapped
along her parents when she was 2 years old and then
appropriated by a member of the police forces, was
returned to her biological family with the help of these
genetic studies.
In 1987 by National Law 23,511, it was the National
Bank of Genetic Data (BNDG) was created, whose aim is
to collect the genetic profiles of all relatives of missing
grandchildren in order to compare them with potential
“kidnapped” children. This bank was the seed and inspira-
tion to many other genetic banks that sprouted in the early
nineties in order to identify missing people, victims of
human trafficking, and stealing of children (ICMP 2018).
Different and new forensic genetic techniques were
employed and added during the following years. Initially
histocompatibility and maternal lineage studies using mito-
chondrial DNA sequencing enabled the recovery of grand-
children in Argentina (Orrego & King, 1990) Later,
polymerase chain reaction (PCR) also contributed to the
development of new genetic markers, both in autosomal
and sex chromosomes. (Ruitberg, Reeder, & Butler, 2001).
Thirty years after the creation of the BNDG, new mathe-
matical advancements were applied to the identification of
missing people (Kling, Egeland, Piñero, & Vigeland, 2017)
as well as new software specialized in massive search for
Missing People Identification (MPI) and Disaster Victim
Identification (DVI) (Brenner, 2006; CODIS 1990; Ege-
land, Mostad, Mevåg, & Stenersen, 2000; Kling, Tillmar,
& Egeland, 2014). Table 1 shows a summary of methods
employed along the years.
Up to date, 127 identifications have been achieved, 50
of them were completed without need of genetic testing,
(34 children had been already born when kidnapped and
directly recognized by their families, while other 16 have
never been born as their mothers were found dead and bur-
ied as “No Name” and the burial dates were incompatible
to them giving birth before being killed). Figure 2 shows
the number of genetic‐based grandchildren recoveries per-
formed by the BNDG over the years. Posterior analysis of
the documentation of the 111 living recoveries demon-
strated a behavior pattern in the appropriation felonies.
About 70% of the children were registered as biological
with certificates of domiciliary births signed by obstetri-
cians linked to the Armed Forces or in clinics associated
with baby trafficking. Additionally, 85% of these babies
were appropriated by couples belonging to the Armed
Forces or related to them. The results obtained by the
BNDG also served as proof in the numerous trials for
crimes against humanity perpetuated in our country (Data
supplied by Unidad especializada para casos de apropiación
de niños durante el terrorismo de Estado. https://www.fisca
les.gob.ar/unidad-de-apropiacion/).
The archives of the BNDG evidence the history and
evolution of forensic genetics and are unique in a way that
there is no other database for the search and identification
of appropriated children in the world (Lerman, 2017). The
persistent fight carried by las Abuelas de Plaza de Mayo
(The Grandmothers of Plaza de Mayo) allowed science to
stand by the side of the Human Rights, to not be used as a
tool for discrimination, but for the right of identity and
TABLE 1 Evolution and incorporation of forensic genetics
techniques during the 30 years of the National Bank of Genetic Data
(BNDG)
Stage
Time
frame Methods
Exploratory 1984–1992 HLA, RFLP, and early PCR
Stabilization 1992–2005 Mitochondrial DNA sequencing,
autosomal and chromosome Y
microsatellite standardization and
quality controls
Growth 2005–2018 Chromosome X Microsatellites.
Automatization. Software for
massive searchs (DVI, MPI)
Note. DVI: disaster victim identification; HLA: human leukocyte antigen;
MPI: missing people identification; PCR: polymerase chain reaction; RFLP:
restriction fragment length polymorphism.
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repairment of serious violations to human kind. (Stern,
2013 March). This year 2018, las Abuelas de Plaza de
Mayo have been nominated for the sixth time to Nobel
Peace Prize for their labor in Humans Rights (Por los más
de 40 años de lucha, 2018).
4 | MEDICAL GENETICS
The first medical GENETIC services in Argentina started
in the late 1960s brought by pediatricians and obstetricians
trained abroad. The National Center of Medical Genetics
(CENAGEM), under the National Ministry of Health, was
established in 1969, followed by other genetic services
located in the main pediatric hospitals. However, the devel-
opment of medical genetics services in Argentina lacked a
planned strategy.
In 1979, CENAGEM started a medical genetics resi-
dency, which was followed by the cytogenetics resi-
dency. In the early years of 21st century, different
surveys showed that health professionals in Argentina
still had little knowledge of medical genetics (Barbero et
al., 2003). Ten of the 24 jurisdictions had no genetic
services in the public healthcare sector, with most of the
services settled in the central region of the country
(Liascovich, Rozental, Barbero, Alba, & Ortiz, 2006) and
no coordination between services due to dependency
from multiple authorities (academic, municipal, provin-
cial, and/or national). Some practices, such as prenatal
diagnosis, were only offered in the private setting. It is
important to note, that since abortion has been illegal
unless the life or health of the mother is at risk, or in
case of rape, (an issue which is currently under intense
debate in the congress), the development of prenatal
diagnosis in the public setting is stagnant (Penchaszadeh,
2013).
Promoted by the CENAGEM, the National Program of
the Genetics Network was designed in 2008 through a
decree issued by the National Ministry of Health (Resolu-
tion 1227/2008). This program aimed to build a network
of genetic services from the public sector and train health-
care professionals in medical genetics. Since 2012, each
province appointed a local healthcare professional to work
with the central coordination of this National Program.
The central coordination of the program trained locally
selected health professionals, which led to strengthen local
genetic services. Among new initiatives addressing birth
defects in Argentina, there is a new area working on sur-
veying, diagnosing, and treating rare diseases, organized
after a national law on the topic was enacted (National
Law 26.689, 2011). Nowadays, most genetics services
make clinical and cytogenetic diagnoses and only a few
FIGURE 2 Grandchildren restored to their families by year by DNA analysis performed in the National Bank of Genetic Data (BNDG)
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perform molecular diagnostics for some specific mono-
genic diseases.
5 | NEONATAL SCREENING OF
GENETIC DISORDERS
Newborn screening (NBS) describes the procedures that,
if performed during the first few hours or days of a new-
born's life, have the potential of preventing severe health
problems, including death. Traditionally based on bio-
chemical studies, evolution of NBS has boosted in the
genomic era, nowadays being able, in principle, to cover
—or detect—hundreds of conditions for which early
detection and treatment modify the outcome (Friedman et
al., 2017). In Latin America, NBS began in the early 70s
with the Cuban experience, quickly followed by Argen-
tina and other countries. (Borrajo, 2007; Therrell &
Adams, 2007; Therrell et al., 2015). Each country,
depending on the health circumstances and available
resources, offers a different program regarding disorders,
methodology, and screening strategies.
In Argentina, the neonatal screening program for congen-
ital hypothyroidism (CH) and phenylketonuria (PKU) carried
out by “Fundación de Endocrinología Infantil” (FEI)—a
nonprofit institution closely related to the Division of
Endocrinology Research in the Buenos Aires Children's
Hospital R. Gutiérrez started in August 1985 with the sys-
tematic detection of these diseases in several maternities
along the country (Chiesa et al., 2013). Initially, screening
was not mandatory by law; thus, it was implemented by “re-
quest.” The slogan “a single drop of blood can prevent a sea
of tears” aimed to call the attention of parents and doctors
about the need of testing every baby. As awareness of doc-
tors and health authorities grew, screening practices began to
increase, and FEI became the referent organization for guide-
lines for National NBS development.
In 1986, national law (Law Nr. 23,413) obliged to test
every newborn for PKU. CH and Cystic Fibrosis (CF) were
added also by law in 1990 and 1994, respectively. Finally,
with the approval of a new law in 2007 (Law Nr. 26,279), it
was stated that every newborn in Argentina had to be tested
to detect and treat PKU, CH, CF, galactosemia, congenital
adrenal hyperplasia, biotinidase deficiency, preterm retinopa-
thy, Chagas disease, and syphilis. Moreover, the law stated
that other diseases (genetic, metabolic, or congenital) inap-
parent at birth should be screened if there was a medical jus-
tification and/or political health needs (MSAL 2011).
The first public funding program (PRODYTEC) for
NBS was held in 1995 by the Argentine Biochemical
Foundation (FABA) in Buenos Aires province and in 2001,
Buenos Aires’ city government started its own program
giving full coverage to babies born in the city's public
maternity hospitals. In the national arena, the “National
Program for Neonatal Screening Strengthening” was held
in 2006 with the aim of helping those provinces without
NBS programs or with them but experiencing difficulties.
Although each province had its own NBS laboratory, the
experience was centrally coordinated in Buenos Aires.
Following international guidelines, other diseases were
consecutively included in many of these programs. Nowa-
days, screening for all previous stated diseases are per-
formed routinely in all programs, while Maple Syrup Urine
Disease (MSUD) was included in the Buenos Aires Pro-
vince, FEI, and the Buenos Aires City programs. Since
2014, with availability of the MS/MS methodology, the
Buenos Aires City program began with Medium‐chain
acyl‐CoA dehydrogenase (MCAD) deficiency screening.
Although the estimated coverage of NBS in Argentina
surpasses 90% of newborns, it is important to mention that:
(a) not all the babies are tested for the same disorders or
undergo the same procedures and (b) not all studies neces-
sarily follow a precise molecular genetic diagnostic test
(i.e., identification of mutation responsible for disease
development).
Table 2 shows the number of newborns screened and
the mean estimated incidence of each disorder since the
start of the FEI NBS screening program (1985), the Bio-
chemical Foundation screening program (1995), the Buenos
Aires City screening program (2001), and the National pro-
gram for the strengthen of neonatal screening (2006), up to
December 2017 (kindly provided by each program). The dis-
ease marker, methodology, and cutoff chosen for detection
may have varied between programs and along the years, but
the data included assure the correct interpretation and confir-
mation of every case. As shown, primary CH, screened by
TSH levels, is the most prevalent condition in the
population. Congenital adrenal hyperplasia—mainly the salt
wasting forms—is detected by the neonatal rise in 17
OH‐progesterone levels, evidencing the enzymatic blockade.
The search for hyperphenylalaninemia is based on the deter-
mination of phenylalanine levels or on the phenylalanine/ty-
rosine ratio, when MS/MS methodology is available. The
disease is more frequent in populations with European
ancestors and less frequent in those regions with more native
ethnicity, so dissimilarities in incidence may be found by
different programs (Borrajo, 2016). CF is prevalent in our
population and its screening is complex because immunore-
active trypsin (IRT) is a relatively weak marker. For that rea-
son, a second step has to be added to the screening strategy.
In our country, another IRT or pancreatitis‐associated pro-
tein (PAP) assay is preferred over molecular testing for con-
firmation, due to its lower cost. Total galactose allows the
identification of the galactosemic state produced by any of
the three enzymatic defects in the galactose pathway. Detec-
tion of Biotinidase deficiency is worth screening for in our
VISHNOPOLSKA ET AL. | 5
population where total and partial forms are found. Finally,
MSUD is not frequent in our population and the recently
included screening for MCAD does not have enough num-
ber of screened babies to reflect its real incidence.
6 | SURVEILLANCE OF BIRTH
DEFECTS
Birth defects (BD), also called congenital anomalies, are
structural or functional defects that originate during the pre-
natal period. BD are etiologically heterogeneous, either
multifactorial (predisposing genes that are expressed in the
presence of environmental triggers), predominantly genetic
(chromosomal or monogenic abnormalities), or predomi-
nantly environmental (prenatal exposure to teratogenic
agents) (Stevenson, Hall, & Goodman, 1993). Around 94%
of newborns with birth defects are born in low‐ and mid-
dle‐income countries, placing an additional burden on
families, communities, and health systems (Christianson,
Howson, & Modell, 2006).
As previously stated, in Argentina, BD are a leading
cause of infant deaths. Among 7,093 infant deaths that
occurred in 2016, 2,175 (30%) were due to BD (DEIS,
2016). In 2009, members of CENAGEM started the imple-
mentation of the National Network of Congenital Anoma-
lies of Argentina (RENAC). RENAC objectives are to
monitor continuously and systematically the frequency of
BD; respond to alarms linked to possible epidemics of con-
genital anomalies; evaluate risk factors that contribute to
the occurrence of BD in Argentina and the impact of pre-
ventive population interventions; and promote the training
of maternity health teams for the recognition of BD in
newborns and their timely referral to care services
(Groisman, Bidondo, Gili, Barbero, & Liascovich, 2013;
Groisman, Bidondo, Barbero, et al., 2013).
The RENAC is an official and hospital‐based surveil-
lance system, which includes 134 public and 26 nonpublic
hospitals from the 24 provinces of the country. Annual
coverage is approximately 300,000 births, which accounts
for 65% from the public health sector and 38% of all births
in the country (RENAC, 2017). Since 2012, the RENAC
has become an active member of the International Clearing-
house for BD Surveillance and Research (ICBDSR), an
international consortium of BD surveillance programs
(Botto et al., 2006). To ensure proper data collection, in
each participating hospital, there are two RENAC “champi-
ons.” These motivated health professionals (neonatologists,
pediatricians, or nurses) are in charge of collecting informa-
tion about the affected cases and sending the data to the
RENAC coordination through a web‐based forum. The
website allows sending data, photographs, solving opera-
tional issues, and providing quality control of data. Mem-
bers of the RENAC coordination have expertise in medical
genetics and epidemiology.
Surveillance systems have a big potential for early
detection of infants with BD, thus allowing referral to
adequate health services (Botto & Mastroiacovo, 2000).
As already mentioned, many physicians are not trained in
the basics of medical genetics and Argentina has few and
scattered genetic services, with some provinces having no
genetic service at all (Liascovich et al., 2006). In this
context, RENAC has developed guidelines for the consul-
tation of patients and the training of health professionals
in medical genetics. RENAC champions can enter the
web forum at any time and post messages with patient
photographs, x‐rays, laboratory results, and other studies
that allow discussion of the clinical case (Groisman,
TABLE 2 Incidence of diseases screened referred to the number of screened newborn as reported by four NBS Argentinean programs (1985–
2017) in Argentina
Disease Disease marker
Number of screened
babies up to 12/2017 Incidence
Congenital hypothyroidism TSH 8,855,085 1:1,938
Congenital adrenal hyperplasia 17OH Progesterone 5,426,789 1:14,004
Phenylketonuria/hyperphenylalaninemia Phenylalanine 8,891,158 1:31,087
1:31,754
Cystic fibrosis (IRT‐IRT)/(IRT‐PAP) 5,444,430 1:8,753
Galactosemia Total galactose 5,670,649 1:63,000
Biotinidase deficiency Biotinidase activity 5,232,514 1:120,000
Maple syrup disease Leucine 1,345,061 1:149,451
Medium chain AcylcoA dehydrogenase
deficiency (MCAAD)
C8
C10
112,926 1:112,926
Note. C10: decanoylcarnitine; C8: octanoylcarnitine; IRT: immunoreactive trypsin; PAP: pancreatitis‐associated protein; TSH: thyroid‐stimulating hormone.
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Bidondo, Gili, et al., 2013). RENAC coordination con-
tributes in diagnosis, detection of associated birth defects,
providing tools for basic genetic counseling, and referral
to genetic services. By belonging to RENAC, local teams
in maternity hospitals can receive help in the diagnosis of
complex cases with rare or multiple defects, or at life
risk, whose families require support and counseling. This
significantly improves patients’ health and their families
leave the maternity wards with a presumptive diagnosis
that allows a shorter diagnostic journey and a proper
follow‐up.
Regarding BD prevalence in the country, the
most frequent BD reported by RENAC in 2016 were
down syndrome, talipes, critical congenital heart defects,
neural tube defects, and cleft lip with cleft palate
(Table 3).
The CENAGEM and national NBS and RENAC BD
surveillance program provide the pillars for the application
of medical genetics in Argentina as well as carrying
training initiatives for healthcare professionals. They are
ideally suited and expected to increasingly adopt the new
genomic technologies in the upcoming years. Interestingly,
and as will be shown below, entry to the genomic era
was initially performed by research and academia‐based
initiatives.
7 | THE GENOMIC ERA IN
ARGENTINA
With the aim of implementing and settling the basis for
genomic studies in the country, in 2012, the Argentinean
Genomic and Bioinformatic Platforms were created as ini-
tial 4‐year projects, with the help and financing of the
National Ministry of Science and Technology (MINCyT).
The main aims of these platforms were to develop and
transfer genomic and bioinformatic knowledge as well as
facilitating those services to public and private parties.
It was during this period that, in collaboration with the
local hospital “Hospital de Agudos Ramos Mejia,” the very
first three whole genomes were entirely sequenced in the
country: the hospital made the link with the patients and
their family and got written consent from all individuals
involved, DNA was extracted and sequenced in INDEAR
(Agrobiotechnology institute of Rosario), as member of the
genomic sequencing platform, and bioinformatic analysis
was performed in the bioinformatic platform in Buenos
Aires (www.biargentina.com.ar). These genomes comprised
three siblings, all with autism spectrum disorder, whose
careful analysis finally led to the discovery of a shared de
novo variant in the SHANK3 gene (OMIM 606230, Gen-
bank NM_033517) (Nemirovsky et al., 2015). Following
this first success, it was important to continue expanding
the reach of new generation sequencing technologies and
genomic studies to a broader group of medical specialists
and patients with rare genetic diseases and no molecular
diagnosis, countrywide.
With this idea in mind, in 2016, we launched a new
project whose aim was to sequence 100 exomes of patients
with rare genetic disorders throughout the country. The
“100 Exomes Campaign” was jointly financed and per-
formed by the research group of Dr. Marti and Dr. Turjan-
ski at the Department of Biological Chemistry of the
Faculty of Science of the University of Buenos Aires, and
Bitgenia (www.bitgenia.com), a local Genomics company
(Bitgenia, 2016). The exomes were sequenced at no cost
for the patients and their families, and we performed all
downstream analysis also free of charge. Variant prioritiza-
tion was performed, whenever possible, jointly with the
healthcare professionals in order to train them in the inter-
pretation of genomic data. Results were provided to the
TABLE 3 Prevalence of selected birth defects over 305,452
births, RENAC, 2016
Birth defect (ICD‐10 RCPCH)
Total
cases
Prevalence per
10,000 (CI 95%)
Critical congenital heart defectsa 353 11.56 (10.38–12.83)
Neural tube defects (Q00, Q01, Q05) 270 8.84 (7.82–9.96)
Anencephaly (Q00) 57 1.87 (1.41–2.42)
Spina bifida (Q05) 175 5.73 (4.91–6.64)
Encephalocele (Q01) 39 1.28 (0.91–1.75)
Cleft lip only (Q36, excluding Q36.1) 59 1.96 (1.50–2.53)
Cleft lip and palate (Q37) 341 11.16 (10.01–12.41)
Cleft palate only (Q35) 99 3.24 (2.63–3.95)
Hypospadias (Q54.1–Q54.3) 46 2.65 (2.11–3.30)
Limb deficiencies (Q71–Q73) 153 5.01 (4.25–5.87)
Transverse (Q71.2–Q71.30 42 1.38 (0.99–1.86)
Preaxial (Q71.31, Q72.5) 19 0.62 (0.37–0.97)
Postaxial (Q71.5; Q72.9) 10 0.33 (0.16–0.60)
Talipes (Q66) 378 12.4 (11.2–13.7)
Equinovarus (Q66.0) 180 5.89 (5.06–6.82)
Calcaneovalgus (Q66.4) 16 0.52 (0.30–0.85)
Microtia/anotia (Q16; Q17.1) 88 2.88 (2.31–3.55)
Polydactyly (Q69) 239 7.8 (6.9–8.9)
Preaxial (Q69.00;Q69.1;Q69.20) 46 1.51 (1.10–2.01)
Postaxial (Q69.02; Q69.22) 148 4.85 (4.10–5.69)
Omphalocele (Q79.2) 66 2.16 (1.67–2.75)
Gastroschisis (Q79.3) 239 7.82 (6.86–8.88)
Down syndrome (Q90) 548 17.94 (16.47–19.51)
aQ20.0, Q20.3, Q20.4, Q21.3, Q21.82, Q22.00, Q22.40, Q22.5, Q23.4,
Q25.1–Q25.19, Q25.2, Q26.2, Q26.20.
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physician in charge, so they could offer proper genetic
counseling to the patients involved in the project.
Throughout the campaign, the project involved 58
health professionals working in 32 different public or pri-
vate institutions, and included patients with a variety of
clinical diagnostics such as cardiopathies, skin disorders,
familial cancer, neurodevelopmental disorders, cranial mal-
formations, inborn errors of the metabolism, mitochondrial
disorders, endocrine disorders, absorption disorders, and
primary immunodeficiencies or autoimmune disorders, for
naming some. Among the 100 analyzed cases, for 31, we
found one or more known pathogenic variants with
reported evidence of association with the initial diagnosis,
while for another 27 cases, we found novel likely patho-
genic variants in genes previously associated with disease.
Some of these variants were then confirmed to cause dis-
ease by functional studies in collaboration with other
groups (Ma et al., 2017). We consider these cases, which
represent about 50% of those sequenced, as potential suc-
cessful diagnostics, clearly highlighting the potential of
whole exome sequence for medical genetics.
8 | NATIONAL GENOMICS DATA
SYSTEM
A parallel initiative to promote and coordinate the development
of genomic technologies and data sharing, led to the creation of
The National Genomics Data System of Argentina (SNDG by
its name in Spanish: Sistema Nacional de Datos Genómicos,
http://www.datosgenomicos.mincyt.gob.ar/) in 2015, under the
Ministry of Science, Technology and Innovation (Ministerial
Resolution 761/14). The SNDG emerged as a natural conse-
quence of different initiatives—including the mentioned Bioin-
formatics Platform—and due to the establishment of several
local bioinformatics and genomics research groups. Taking this
into account, the development of a national system to organize
the data generated by the different projects around the country
became an imperative goal.
The main objective of the system is to establish an unified
national database of genomic information, for all species of
ecological, agricultural, biotechnological, and health interest,
derived from research and surveys taken into place or funded
by the country, warranting Argentinean researchers their avail-
ability and accessibility . Parallel objectives also include train-
ing local researchers in how to generate and analyze genomic
data, generating a local interdisciplinary and cooperative com-
munity of laboratory scientists and bioinformaticians, promot-
ing and facilitating the generation of genomic information,
generating quality standards both for generation and analysis
of genomic data, and promoting the development of bioinfor-
matic tools locally. Since its creation, the SNDG incorporated
more than 20 centers around the country, gave grants to more
than 10 projects related to genomics, and generated the pipe-
line and web portal to upload and analyze genomic data.
9 | THE PRESENT I: BOOSTING
MOLECULAR DIAGNOSTICS
Nowadays genomics medicine is flooding Argentina,
since most government supported initiatives from both
Health and Science central agencies, private healthcare
institutions and clinical diagnostic laboratories are offer-
ing genomic services, either supervised by healthcare
professionals or with a direct to consumer sales model.
These genomic services offer either precise molecular
tests for (rare) Mendelian diseases (González‐Morón et
al., 2017) ‐using both whole exome or panel‐based
sequencing‐; evaluation of cancer risk ‐mainly based on
BRCA1/2 genes analysis (OMIM 113705, NM_007300;
OMIM 600185, NM_000059) (Israel, 2013); or Non Inva-
sive Prenatal Testing (NIPT) (Vázquez et al., 2017) of
chromosomal anomalies. Sequencing is either performed
locally (currently there are between 10–20 next generation
sequencers in health centers in the country) or outsourced
abroad. The same is true for the analysis of raw data
and/or interpretation of results in a clinical context, with
several health‐ or research‐based institutions harboring
clinical genomics interpretation services (or even research
groups, such as our own). Prices also vary greatly, possi-
bly due to inherent differences in the nature of the pro-
vided service. They can be as high as 2,000 USD for a
complete service, including sequencing and clinical inter-
pretation, and possibly no lower than 400 USD. Interest-
ingly, there is no correlation between the amount of
sequenced/analyzed data and the total cost (i.e, a whole
exome is not necessarily more expensive than a gene
panel).
The wider access to genomic services (for both provi-
ders and consumers), together with increased presence of
genomic‐related content in the local media, is creating an
increasing demand of genomic interpretation services in
our country, which contrasts with the scarce number of
trained professionals in clinical genomics and related areas.
To overcome this issue, not only are specialized courses in
genomics for scientists and healthcare professionals needed
(such as the “School of Clinical Genomics” which is held
every August at the local Department of Biological Chem-
istry and financed by the Centro Latinoamericano de For-
mación Interdisciplinaria, CELFI, http://www.celfi.gob.ar/
programas/detalle?p=100) but a significant increase of
Molecular Genetics training in basic physicians curricula
would also be welcomed. However, the current lack of
local regulation of these kind of services constitutes a big
setback, a fact that not only impacts the quality of the
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results and ethical issues related to patients’ rights but also
is tightly related to people's accessibility in the context of
Argentina's healthcare system. This lack of proper regula-
tion of clinical genomic services ultimately results in an
accessibility bias toward the higher income strata of
society.
10 | THE PRESENT II: ARGENTINA'S
“PRECISION MEDICINE
INITIATIVE”
In 2017, Argentina's Ministry of Science and Technology
launched a Precision Medicine Initiative Grant whose aim
was to establish the scientific know‐how and protocols
required to implement “omic” technologies in the clinical
practice, by performing a proof of concept of the process
in a small number of patients. Three grants were awarded,
including ours which targeted “Clinical Genomics of Pedi-
atric Diseases,” one related to the creation of a National
Biobank, and the third related to cancer genomics. Projects
involve both healthcare institutions harboring NGS equip-
ment and research groups from academia, thus displaying a
high potential for synergic collaboration. Our project
started in early 2018 and is expected to develop several tar-
geted sequencing panels for pediatric disease groups and
analyze a cohort of about 1000 patients in the following
years.
This initiative shows that precision medicine and geno-
mics are part of the political scientific agenda; however, it
is difficult to guess the real impact that these projects are
going to have on the overall healthcare system.
11 | CONCLUDING REMARKS
Argentina is a country with inequalities in terms of health-
care, including medical genetics. Although all inhabitants
(and immigrants) by law are granted access to health ser-
vices, the fragmented system of public, social security, and
private funding contributes to wide disparities in the popu-
lation's effective use of key technologies, especially in the
genetics and genomics area.
The use of genetic testing in the forensics field for the
recovery of appropriated grandchildren and the fight for
human rights seems to have had little influence on human
health in Argentina. Until now, the vast majority of physi-
cians trained in the country have little knowledge of genetics
and the underlying molecular basis of human diseases.
In this context, it is important to highlight the efforts of
several public organizations such as BNDG, CENAGEM,
RENAC, NBS Program, and local hospitals in training
healthcare professionals in medical and molecular genetics
and developing new initiatives available for the Argen-
tinean population.
Concerning genomics, the first genomes sequenced and
the “100 Exome” campaign serve as a proof of concept,
that it is possible to implement a local molecular diagnosis
service based on next generation sequencing for research
and clinical innovation. The implementation was based on
the knowledge and capacity of local professionals. It is an
example of how these projects can be set and then
expanded in a national fashion, with guidelines and proto-
cols adapted from the already existent internationally avail-
able services to satisfy the regional needs. Key to success
of any of these techniques in the daily life of scientists and
physicians is to create links between the different agents of
change, to truly create interdisciplinary teams capable of
tackling the problems that are sure to arise.
Next steps to strengthen the quality and availability of
these genetic analyses include the creation of local human
genetic databases of variant frequencies that truly represent
the genetic imprint of the Argentinean population, which is
underrepresented in international databases, with a ques-
tionable “Latino” ethnicity component, that fails to truly
represent the Amerindian ancestry of Argentina and other
Latin American countries.
In the public health and political field, new initiatives are
required to expand the results achieved by the initial projects
in the area of genomics. Some public pediatric hospitals, such
as Hospital de Niños Dr. Ricardo Gutiérrez and Hospital Gar-
rahan, have recently acquired some next generation sequencers
and are already using them for diagnosing different patholo-
gies. Moreover, several health insurance companies are starting
to acknowledge the utility of these genomic tests and to cover
the costs of diagnosis using these technologies. However, there
is much to be done to expand the access to these tests to the
whole population. Most advances are made in the central
region of the country, while the other regions fall behind. In
this case, it is imperative that policy makers of the country
take into consideration this reality and promote the access and
availability of these services in an ethical and egalitarian way.
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